Pharmacokinetics and Pharmacodynamics of the Glucagon Receptor Antagonist LGD-6972 in a Multi-dose Clinical Trial

被引：0
|
作者：
Vajda, Eric G.
Logan, Douglas
Lasseter, Kenneth
Armas, Danielle
Plotkin, Diane
Pipkin, J. D.
Li, Yong-Xi
Zhou, Rong
Klein, David
Wei, Xiaoxiong
Dilzer, Stacy
Zhi, Lin
Marschke, Keith B.
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1193-P
引用
收藏
页码：A308 / A308
页数：1
相关论文
共 50 条
  • [21] The Influence of Multiple-Dose Vorapaxar, an Oral PAR-1 Receptor Antagonist, on the Single-Dose Pharmacokinetics and Pharmacodynamics of Digoxin
    Kosoglou, Teddy
    Zhu, Yali
    Statkevich, Paul
    Xuan, Fengjuan
    Schiller, James E.
    Johnson-Levonas, Amy O.
    Cutler, David L.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2013, 2 (01): : 90 - 98
  • [22] Flexible, Multi-dose GnRH Antagonist versus Long GnRH Agonist Protocol in Poor Responders: A Randomized Controlled Trial
    Tehraninejad, Ensieh Shahrokh
    Fazel, Azadeh
    Samiei, Arash
    Rashidi, Batool
    Kiani, Kiandokht
    INTERNATIONAL JOURNAL OF FERTILITY & STERILITY, 2009, 2 (04) : 165 - 168
  • [23] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of macitentan, an Endothelin Receptor Antagonist, in an Ascending Multiple-Dose Study in Healthy Subjects
    Sidharta, Patricia N.
    van Giersbergen, Paul L. M.
    Dingemanse, Jasper
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (11): : 1131 - 1138
  • [24] Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects
    Sidharta, Patricia N.
    van Giersbergen, Paul L. M.
    Dingemanse, Jasper
    PHARMACOLOGY, 2018, 102 (5-6) : 339 - 346
  • [25] TOXICOLOGY STUDIES IN SUPPORT OF THE UK CF GENE THERAPY CONSORTIUM'S MULTI-DOSE CLINICAL TRIAL
    Griesenbach, U.
    McLachlan, G.
    Collie, D.
    Innes, J.
    Higgins, T.
    Cheng, S.
    Scheule, R.
    Alton, E. W.
    Davies, J. C.
    Hyde, S. C.
    Porteous, D.
    Boyd, A. C.
    PEDIATRIC PULMONOLOGY, 2011, : 298 - 298
  • [26] SPATIAL AND TEMPORAL SEPARATION OF CELLULAR THERAPY PRODUCTS FOR A MULTI-DOSE AND MULTI-CENTER PHASE II CLINICAL TRIAL
    Hodgins, S.
    Khan, S.
    Mei, S. H.
    Stewart, D. J.
    Courtman, D. W.
    CYTOTHERAPY, 2017, 19 (05) : S76 - S76
  • [27] Toxicology studies in support of the UK CF Gene Therapy Consortium's Multi-dose Clinical Trial
    Griesenbach, Uta
    McLachlan, Gerry
    Collie, David D.
    Innes, J. Alastair
    Higgins, Tracy E.
    Cheng, Seng H.
    Scheule, Ronald K.
    Alton, Eric W. F. W.
    Davies, Jane C.
    Hyde, Steve C.
    Gill, Deborah R.
    Porteous, David J.
    Boyd, A. Christopher
    HUMAN GENE THERAPY, 2012, 23 (05) : A12 - A12
  • [28] Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study
    Wong, YN
    Rossignol, D
    Rose, JR
    Kao, R
    Carter, A
    Lynn, M
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (07): : 735 - 742
  • [29] Multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy human subjects
    Sidharta, PN
    van Giersbergen, PLM
    Schaarschmidt, D
    Dingemanse, J
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (06) : 677 - 678
  • [30] Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ETA endothelin-receptor antagonist SPP301 in man
    Dieterle, W
    Mann, J
    Kutz, K
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2005, 43 (04) : 178 - 186
12345